Public Funding for Predictimmune Limited

"Immune-mediated diseases, including autoimmune and inflammatory diseases, are common, debilitating and immensely heterogeneous: two patients diagnosed with the same disease may follow markedly different clinical courses. For many autoimmune diseases, effective and often expensive treatments are now available. However, the immunosuppression they induce also results in substantial side effects. Consequently, there is an increasing need for clinical assays that allow physicians to tailor these potentially toxic immunosuppressive therapies to the right patients at the right time. However, there are currently no robust clinical or biomarker assays that allow personalized therapeutic targeting in these diseases. PredictImmune is developing pioneering tools for guiding treatment options in immune-mediated inflammatory diseases with its first product addressing inflammatory bowel disease (both Crohn's disease and ulcerative colitis). In order to fully achieve the goal of personalized medicine in inflammatory bowel disease, it is necessary to demonstrate more than just prediction but also to show that clinical outcomes can be improved if aggressive therapy is matched to patients predicted to follow an aggressive disease course. This will be the goal of the feasibility study presented here."